Quick answers

What is 5-Amino-1MQ and what is it used for in research?
5-Amino-1MQ is classified within the Body Recomposition group. Selective, membrane-permeable NNMT (nicotinamide N-methyltransferase) inhibitor. In preclinical models, inhibition of NNMT in adipose tissue preserves SAM/methyl donors, elevates cellular NAD+, and reduces adiposity while improving metabolic flexibility. Research applications focus on the pathways outlined below. All references on this page describe published research only, 5-Amino-1MQ is supplied for in-vitro and laboratory use, not for human consumption.
How does 5-Amino-1MQ work?
Primary mechanism: Small-molecule NNMT inhibitor; preserves methyl donors and raises cellular NAD+. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for 5-Amino-1MQ remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical 5-Amino-1MQ research dose?
Published research protocols for 5-Amino-1MQ describe per-dose ranges of 2–5 mg / day, with a weekly total near 14–35 mg, administered oral daily. Typical cycle: 8–12 weeks. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy 5-Amino-1MQ in Thailand?
5-Amino-1MQ is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can 5-Amino-1MQ be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is 5-Amino-1MQ?

5-Amino-1MQ is a research peptide in the Body Recomposition class. Small-molecule NNMT inhibitor; preserves methyl donors and raises cellular NAD+. It is studied at per-dose ranges of 2–5 mg / day (14–35 mg weekly), administered oral daily over cycles of 8–12 weeks. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

Selective, membrane-permeable NNMT (nicotinamide N-methyltransferase) inhibitor. In preclinical models, inhibition of NNMT in adipose tissue preserves SAM/methyl donors, elevates cellular NAD+, and reduces adiposity while improving metabolic flexibility.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does 5-Amino-1MQ work?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT methylates nicotinamide to 1-methylnicotinamide, consuming SAM and redirecting nicotinamide away from NAD+ salvage. Inhibiting NNMT preserves cellular NAD+ pools and SAM availability, with preclinical readouts in adipocyte lipolysis, muscle energy metabolism, and metabolic flexibility. Strictly speaking this is a small-molecule inhibitor, not a peptide, but it is catalogued here alongside other metabolic research compounds.

Receptor binding affinity and post-receptor signalling for 5-Amino-1MQ remain areas of active investigation; several proposed effects within the Body Recomposition class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

5-Amino-1MQ pharmacokinetics

Half-life
Small-molecule pharmacokinetics: preliminary rodent data describe an oral half-life on the order of several hours; comprehensive human PK is not yet published.
Bioavailability
Oral bioavailability is the distinguishing feature vs. injectable peptides in the catalogue.
Route of administration
Oral administration is the standard route in published and ongoing research.
Metabolic clearance
Hepatic and renal clearance pathways; detailed metabolite profiling published in the medicinal-chemistry literature.

5-Amino-1MQ research timeline

  1. 2018 Neelakantan et al., selective, membrane-permeable small-molecule NNMT inhibitors characterised (Biochem Pharmacol).

5-Amino-1MQ dosage & protocol

Reference protocol for 5-Amino-1MQ (research context only, drawn from published literature):

  • Per dose: 2–5 mg / day
  • Weekly total: 14–35 mg
  • Frequency: Oral daily
  • Cycle: 8–12 weeks

5-Amino-1MQ injection & handling

Reconstitution
Oral compound, no reconstitution required; supplied as powder or capsule.
Storage
Dry powder stored at room temperature in a sealed container protected from light and moisture.
Sites used in the research literature
Oral dosing, typically 2–5 mg per day in research-dosing literature.

Handling notes reflect methods used in published research protocols, not medical dosing guidance.

Order 5-Amino-1MQ
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about 5-Amino-1MQ ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking 5-Amino-1MQ

Commonly referenced pairing with 5-Amino-1MQ: Monotherapy. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a 5-Amino-1MQ stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Limited human safety data. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Further reading

Compare 5-Amino-1MQ with: AOD-9604

Citations

  1. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018. PMID: 29155147

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.